<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20621" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Disulfiram</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stokes</surname>
            <given-names>Maranda</given-names>
          </name>
          <aff>Kern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abdijadid</surname>
            <given-names>Sara</given-names>
          </name>
          <aff>UCLA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Maranda Stokes declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Abdijadid declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20621.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Disulfiram is a Food and Drug Administration-approved medication for alcohol dependence. This&#x000a0;activity&#x000a0;discusses disulfiram's&#x000a0;use as an&#x000a0;intervention for both short and long-term management of alcohol dependency in motivated individuals. Participants will explore its mechanism of action, adverse event profile, contraindications, pharmacology, monitoring protocols, and pertinent drug interactions, facilitating a comprehensive understanding among healthcare team members.&#x000a0;This knowledge equips professionals to tailor treatment strategies to individual patient needs, fostering informed decision-making while mitigating potential adverse effects. By&#x000a0;focusing&#x000a0;on the pharmacological intricacies of disulfiram, healthcare providers gain the knowledge to administer personalized care, thereby aiding patients on their journey to sobriety.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the Food and Drug Administration-approved indications for disulfiram therapy.</p></list-item><list-item><p>Identify the mechanism of action of disulfiram corresponding to its indicated use.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse&#x000a0;drug reactions&#x000a0;of disulfiram.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from disulfiram therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20621&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20621">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20621.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Disulfiram&#x000a0;is&#x000a0;1 of&#x000a0;3 drugs&#x000a0;approved by the Food and Drug Administration for the treatment of alcohol dependence.</p>
        <p>
<bold>Food and Drug Administration-Approved Indication</bold>
</p>
        <p>It is a second-line option (acamprosate and naltrexone&#x000a0;are first-line treatments)&#x000a0;in patients with sufficient physician supervision. Disulfiram&#x000a0;is safe and efficient in supervised short-term and&#x000a0;long-term treatment of individuals&#x000a0;dependent on alcohol but who&#x000a0;are&#x000a0;motivated to discontinue alcohol use.<xref ref-type="bibr" rid="article-20621.r1">[1]</xref>&#x000a0;The American Psychiatric Association (APA) 2018 guidelines endorse the use of disulfiram for alcohol use disorder.&#x000a0;According to APA recommendations, disulfiram should be considered for patients exhibiting moderate to severe alcohol use disorder under specific conditions. This includes individuals with a primary goal of achieving abstinence and those who express a preference for disulfiram or demonstrate intolerance or lack of response to naltrexone and acamprosate. Furthermore, candidates for disulfiram treatment should possess the capability to comprehend the risks associated with alcohol consumption while taking the medication, and they should have no contraindications to its use.<xref ref-type="bibr" rid="article-20621.r2">[2]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Current studies for treating patients with comorbid alcohol dependence with post-traumatic stress disorder, alcohol and cocaine&#x000a0;dependence, and cocaine dependence alone are underway.<xref ref-type="bibr" rid="article-20621.r3">[3]</xref><xref ref-type="bibr" rid="article-20621.r4">[4]</xref><xref ref-type="bibr" rid="article-20621.r5">[5]</xref>&#x000a0;A&#x000a0;systematic review presents promising evidence regarding the efficacy of disulfiram as a potential intervention for cocaine dependence. The synthesis of data from 13 studies, encompassing 1191 individuals with cocaine addiction, indicates a potential increase in abstinence rates at the end of treatment when comparing disulfiram to a placebo. However, uncertainties persist concerning its impact on both the frequency and quantity of cocaine use. Disulfiram appears to demonstrate a potential advantage in reducing the frequency of cocaine use when contrasted with naltrexone, although its effect on the quantity of cocaine use remains uncertain.<xref ref-type="bibr" rid="article-20621.r6">[6]</xref>&#x000a0;Recent studies of disulfiram&#x000a0;as a proteasome inhibitor&#x000a0;and deoxyribonucleic acid (DNA) demethylating agent show promise for new potential therapeutic uses for malignancy and&#x000a0;fungal infections. Disulfiram may have a primary or adjuvant role in treating drug-resistant fungal infections (particularly <italic toggle="yes">Candida</italic>) and malignancy by inhibiting the ABC drug transport protein responsible for resistance. In addition, evidence shows that metabolites of disulfiram induce p53,&#x000a0;mediating apoptosis and cell death. Investigations&#x000a0;of the role&#x000a0;of disulfiram as an anti-cancer and antimicrobial agent are ongoing.<xref ref-type="bibr" rid="article-20621.r7">[7]</xref><xref ref-type="bibr" rid="article-20621.r8">[8]</xref><xref ref-type="bibr" rid="article-20621.r9">[9]</xref></p>
      </sec>
      <sec id="article-20621.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Disulfiram converts to an active metabolite, diethyldithiocarbamate, in the stomach. In the blood, it changes to diethyldithiocarbamic acid (DDC), which is degraded to form diethylamine and&#x000a0;carbon disulfide. DDC undergoes phase II metabolism, forming sulfoxide and sulfone metabolites. These S-oxidized compounds are potent active metabolites producing the effects of disulfiram.<xref ref-type="bibr" rid="article-20621.r10">[10]</xref><xref ref-type="bibr" rid="article-20621.r11">[11]</xref><xref ref-type="bibr" rid="article-20621.r12">[12]</xref></p>
        <p>
<bold>Alcohol Dependence</bold>
</p>
        <p>Disulfiram irreversibly inhibits aldehyde dehydrogenase (ALDH1A1) by competing&#x000a0;with nicotinamide adenine dinucleotide (NAD) at the cysteine residue&#x000a0;in the enzyme's active site. Aldehyde dehydrogenase is a hepatic enzyme of the major oxidative pathway of alcohol metabolism, converting acetaldehyde to acetate.&#x000a0;At therapeutic doses of disulfiram,&#x000a0;alcohol consumption results in increased serum acetaldehyde, causing&#x000a0;diaphoresis, palpitations, facial flushing, nausea, vertigo, hypotension, and tachycardia. This aggregation of symptoms is known as the disulfiram-alcohol reaction and&#x000a0;discourages alcohol intake.&#x000a0;The reaction is proportional to&#x000a0;both the&#x000a0;dose of disulfiram and alcohol. Thus, disulfiram is not an anti-craving drug and does not modulate the neurobiological mechanism of addiction.</p>
        <p>
<bold>Cocaine Dependence</bold>
</p>
        <p>Disulfiram also inhibits dopamine beta-hydroxylase (DBH), an&#x000a0;enzyme that converts dopamine to noradrenaline, causing an accumulation of dopamine.&#x000a0;Increased dopamine corrects the underlying deficit&#x000a0;in&#x000a0;patients addicted&#x000a0;to cocaine.&#x000a0;Recent studies have shown reduced frequency and amount of cocaine use in patients treated with disulfiram.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Disulfiram is readily absorbed by the gastrointestinal tract, with an 80% to 90% absorption following oral administration.</p>
        <p><bold>Distribution:</bold>&#x000a0;Disulfiram's high lipid solubility facilitates its widespread distribution into fatty tissue throughout the body, and its ability to cross the blood-brain barrier increases&#x000a0;its&#x000a0;distribution&#x000a0;into the central nervous system.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Disulfiram undergoes extensive metabolism in vivo, primarily through reduction, leading to diethyldithiocarbamate (DDTC) formation. DDTC's metabolic fate includes spontaneous degradation in acidic environments like the stomach, yielding diethylamine and carbon disulfide. Another pathway involves the formation of a glucuronide of DDTC through the action of the enzyme glucuronosyltransferase in the liver, contributing to a fraction of the drug excreted in urine. Additionally, thiol methyltransferase enzymes catalyze the methylation of DDTC, resulting in the formation of the lipophilic metabolite DDTC-Me, which plays a role in the irreversible inhibition of the aldehyde dehydrogenase enzyme.<xref ref-type="bibr" rid="article-20621.r7">[7]</xref></p>
        <p><bold>Elimination:</bold> Human studies suggest half-lives of 7 hours for disulfiram and 15 hours for DDTC, indicating significant inter-subject variability in the levels of disulfiram and its metabolites following oral administration.</p>
      </sec>
      <sec id="article-20621.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths </bold>
</p>
        <p>Disulfiram is available only via oral administration. Tablets are&#x000a0;available&#x000a0;in 250 mg to 500 mg forms.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Disulfiram tablets&#x000a0;may be crushed and mixed with liquids (water, coffee, milk, fruit juice) and&#x000a0;should be taken once per day. Disulfiram administration should never take place until the patient has abstained from alcohol for at least 12 hours. Patients should avoid alcohol and alcohol-containing products for at least 14 days after discontinuing disulfiram, as there are reports of disulfiram-alcohol reactions within 2 weeks of discontinuation. There is no benefit to increasing the dose of disulfiram to greater than 500 mg/d.&#x000a0;A trial of disulfiram and alcohol to produce a disulfiram-alcohol reaction is no longer a recommendation. However, the patient should receive extensive education on&#x000a0;symptoms of&#x000a0;disulfiram-alcohol reaction before administration.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>According to recent guidelines from the American College of Gastroenterology (ACG), disulfiram&#x000a0;should not be used&#x000a0;in individuals with liver disease of any spectrum. This is because disulfiram is completely metabolized by the liver and is associated with hepatotoxicity. The use of disulfiram has been linked to idiosyncratic liver injury characterized by an immunoallergenic mechanism. While this adverse reaction is rare, it appears to be more common in individuals with pre-existing liver disease. Additionally, disulfiram does not demonstrate efficacy in preventing the development or progression of liver disease in individuals with Alcohol Use Disorder (AUD).<xref ref-type="bibr" rid="article-20621.r13">[13]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>There are no dosage adjustments for disulfiram provided in the product labeling; use with caution.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The utilization of disulfiram during pregnancy lacks established safety. Therefore, the administration of disulfiram in pregnant individuals should be considered only if, according to the physician's assessment, the anticipated benefits outweigh the potential risks.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>There is a lack of clinical data regarding the administration of disulfiram during breastfeeding. Alternative medications can be considered, particularly when nursing a preterm infant. The drug's labeling advises against the use of disulfiram in nursing mothers.<xref ref-type="bibr" rid="article-20621.r14">[14]</xref></p>
        <p><bold>Pediatric patients: </bold>The safety and effectiveness of disulfiram in pediatric patients have not been established.</p>
        <p><bold>Older patients: </bold>Careful dosage selection of disulfiram is essential for older patients, typically initiating at the lower dosing range. This approach considers the higher occurrence of&#x000a0;reduced hepatic, cardiac, or renal function and the presence of concurrent diseases or&#x000a0;simultaneous drug treatments.</p>
      </sec>
      <sec id="article-20621.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Disulfiram has an acceptable risk profile. However, it is associated with many adverse events and drug-drug interactions, including death. The most common and less serious adverse effects include headache, sleepiness, tiredness, and halitosis (or metallic taste).<xref ref-type="bibr" rid="article-20621.r11">[11]</xref><xref ref-type="bibr" rid="article-20621.r15">[15]</xref><xref ref-type="bibr" rid="article-20621.r16">[16]</xref><xref ref-type="bibr" rid="article-20621.r17">[17]</xref>&#x000a0;Dermatological, neurological, psychiatric, and cardiac events have been reported. Serious&#x000a0;adverse&#x000a0;effects include hepatitis, hepatotoxicity, psychosis, seizures,&#x000a0;peripheral neuropathy, and optic neuritis. Dermatological adverse effects are rare and include exfoliative dermatitis, rash, and pruritis. Hepatic failure may develop after many months of therapy. There have been cases of fatal fulminant hepatic failure that have been reported despite discontinuation of medication (1 in 30,000 patients treated per year).</p>
        <p>Psychiatric adverse effects are rare. Psychosis, confusional states, mutism, headbanging, memory impairment, and rarely stupor&#x000a0;have been reported, and effects are dose-dependent. Symptoms usually resolve after discontinuation of disulfiram and a short course of antipsychotic medication. Psychosis may occur as a result of an interaction between disulfiram and cannabis. Neurological adverse effects may occur as early as 10 days after initiation. Axonal polyneuropathy is a rare adverse effect. Some cases of severe sensory-motor polyneuropathy with the involvement of cranial nerves have been reported within weeks of initiation of&#x000a0;disulfiram&#x000a0;500 mg. Neuropathy occurs in 1 per 1000 patients treated with disulfiram per year.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Drug interactions occur with compounds utilizing the cytochrome P450 enzyme system for oxidative metabolism.<xref ref-type="bibr" rid="article-20621.r7">[7]</xref>&#x000a0;This interaction can occur with the following medications: amitriptyline, imipramine, phenytoin, chlordiazepoxide, diazepam, omeprazole, and acetaminophen. Drug-drug interactions may occur with other medications not listed. Slow elimination of disulfiram may give rise to the disulfiram-alcohol reaction up to&#x000a0;14 days after the discontinuation. Disulfiram-alcohol reactions have been reported in patients exposed to environmental chemical compounds containing alcohol.&#x000a0;Prolonged administration of disulfiram has demonstrated the inhibition of the metabolism of theophylline, phenytoin, and warfarin.<xref ref-type="bibr" rid="article-20621.r18">[18]</xref></p>
      </sec>
      <sec id="article-20621.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Disulfiram is not a safe option for everyone. Disulfiram is contraindicated&#x000a0;absolutely in patients with significant coronary artery&#x000a0;disease or heart failure. Cases of heart failure and death have occurred in patients with severe myocardial disease shortly after the initiation of disulfiram. Disulfiram is contraindicated with psychosis as it may worsen the patient's psychosis. Caution is necessary for patients with a history of liver disease, and the physician must weigh the risks versus benefits. Patients receiving metronidazole, paraldehyde, alcohol, or alcohol-containing&#x000a0;preparations (sauces,&#x000a0;cough mixtures, vinegar)&#x000a0;should not receive disulfiram and should be educated in advance to avoid a disulfiram-alcohol reaction. Disulfiram should never be administered to a patient&#x000a0;if alcohol use is suspected or without the patient's consent and understanding of the disulfiram-alcohol reaction.&#x000a0;Disulfiram may be a therapeutic option with&#x000a0;caution in patients with seizures, diabetes, thyroid disorders, traumatic brain injury, and&#x000a0;renal disease&#x000a0;due to the possibility of an accidental disulfiram-alcohol reaction.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Disulfiram should&#x000a0;<italic toggle="yes">never&#x000a0;</italic>be administered when patients are in a state of alcohol intoxication or without their full knowledge. The clinician should instruct relatives accordingly.</p>
        <p>
<bold>Precautions</bold>
</p>
        <p>In a cross-sectional survey of disulfiram-treated patients, adverse reactions were observed when using alcohol-based hand rubs, common products during the COVID-19 pandemic. This emphasizes the importance of caution and considering alternative hand hygiene methods for individuals on disulfiram.<xref ref-type="bibr" rid="article-20621.r19">[19]</xref></p>
      </sec>
      <sec id="article-20621.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Close monitoring of adverse events is necessary, particularly in patients with polysubstance abuse. Patients taking disulfiram require monitoring for signs and symptoms of hepatitis, including fatigue, weakness, anorexia, nausea, vomiting, jaundice, malaise, and dark urine.<xref ref-type="bibr" rid="article-20621.r20">[20]</xref> Baseline and follow-up liver function tests&#x000a0;should be monitored&#x000a0;10 days to&#x000a0;1 month&#x000a0;following initiation of disulfiram.&#x000a0;Complete blood count and serum chemistries should also require routine monitoring.</p>
      </sec>
      <sec id="article-20621.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>One&#x000a0;case report features a 4-year-old girl who accidentally ingested 4&#x02013;5 tablets of disulfiram, resulting in hypoglycemia and encephalopathy. After management in the intensive care unit, the child exhibited normalization of blood sugars after 8 hours and displayed characteristic MRI brain findings, including bilateral globus pallidus hyperintensity in T2-weighted and diffusion-weighted images. The conclusion underscores the potential severity of acute disulfiram poisoning in children and emphasizes the importance of considering it in the diagnosis of idiopathic encephalopathy with extrapyramidal symptoms.<xref ref-type="bibr" rid="article-20621.r21">[21]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Contact the local poison control center in case of an overdose. No information is available on the treatment of disulfiram overdose, and there is no antidote available. Supportive care via supplemental oxygen, cardiac monitoring, and intravenous fluids may be necessary.&#x000a0;Consult a physician&#x000a0;if symptoms are severe.&#x000a0;Cases&#x000a0;of&#x000a0;ingestion of 5 g or greater resulted in parkinsonism, choreoathetosis, and thalamic syndrome. Doses should not exceed 500 mg/d for treatment of alcohol dependence, and doses for malignancy remain as yet undetermined.</p>
      </sec>
      <sec id="article-20621.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Disulfiram may be prescribed by the primary care provider, psychiatrist, nurse practitioner, or physician assistant. However, all healthcare workers, including the nursing staff and pharmacist, must be familiar with its adverse effect profile. The agent is not well tolerated, and when consumed with alcohol, it can produce severe&#x000a0;adverse effects that can even lead to a heart attack. Today, this drug is not used to treat alcoholism because it is not deemed to be safe.<xref ref-type="bibr" rid="article-20621.r22">[22]</xref>&#x000a0;When using disulfiram requires an interprofessional team approach. Prescribing was covered in the previous paragraph, and the pharmacist should have input regarding dosing and drug-drug interactions by performing complete medication reconciliation and reporting any concerns to the prescribing clinician. Nurses should monitor for treatment effectiveness and adverse reactions to disulfiram and alert the team should any significant adverse event occur.&#x000a0;An&#x000a0;interprofessional team approach and open communication among healthcare professionals, including nurses, specialists, and pharmacists, can optimize patient outcomes related to disulfiram therapy.</p>
      </sec>
      <sec id="article-20621.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20621&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20621">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20621/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20621">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20621.s11">
        <title>References</title>
        <ref id="article-20621.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stok&#x00142;osa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wi&#x00119;ckiewicz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stok&#x00142;osa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piegza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pudlo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gorczyca</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2023</year>
            <month>Jan</month>
            <day>19</day>
            <volume>20</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36767234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reus</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bukstein</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Eyler</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hilty</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Horvitz-Lennon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wills</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>175</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-90</page-range>
            <pub-id pub-id-type="pmid">29301420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Le Foll</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Impact of Substance Use Disorder Pharmacotherapy on Executive Function: A Narrative Review.</article-title>
            <source>Front Psychiatry</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>98</fpage>
            <pub-id pub-id-type="pmid">30881320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Use of Disulfiram for Treatment of Alcohol Addiction in Patients With Psychotic Illness.</article-title>
            <source>Am J Psychiatry</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>176</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-81</page-range>
            <pub-id pub-id-type="pmid">30848944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prescription Drug and Alcohol Use Disorders: Alcohol Use Disorder.</article-title>
            <source>FP Essent</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>478</volume>
            <fpage>30</fpage>
            <page-range>30-42</page-range>
            <pub-id pub-id-type="pmid">30844223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traccis</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Minozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Trogu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vacca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Vecchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pani</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Agabio</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Disulfiram for the treatment of cocaine dependence.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2024</year>
            <month>Jan</month>
            <day>05</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD007024</fpage>
            <pub-id pub-id-type="pmid">38180268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Biniaz-Harris</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kuvaldina</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fallon</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Disulfiram: Mechanisms, Applications, and Challenges.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2023</year>
            <month>Mar</month>
            <day>06</day>
            <volume>12</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">36978391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lajarin-Reinares</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pena-Rodr&#x000ed;guez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ca&#x000f1;ellas-Santos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosell-Vives</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Casas</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>M&#x000c0;</given-names>
              </name>
              <name>
                <surname>Fernandez-Campos</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Repurposing Disulfiram as an Antimicrobial Agent in Topical Infections.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>04</day>
            <volume>11</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">36551409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karsa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ronca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bongers</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spurling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karsa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cantilena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mariana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Failes</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Kotecha</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lock</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Somers</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>FDA-approved disulfiram as a novel treatment for aggressive leukemia.</article-title>
            <source>J Mol Med (Berl)</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>507</fpage>
            <page-range>507-519</page-range>
            <pub-id pub-id-type="pmid">38349407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Budworth</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prestwich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lawton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kotz&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kellar</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Preoperative Interventions for Alcohol and Other Recreational Substance Use: A Systematic Review and Meta-Analysis.</article-title>
            <source>Front Psychol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>34</fpage>
            <pub-id pub-id-type="pmid">30778307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Matson</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AHS</given-names>
              </name>
            </person-group>
            <article-title>Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.</article-title>
            <source>Addict Sci Clin Pract</source>
            <year>2019</year>
            <month>Feb</month>
            <day>12</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">30744686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heldal</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Skurtveit</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lobmaier</surname>
                <given-names>PPK</given-names>
              </name>
              <name>
                <surname>Vederhus</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Bramness</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>[Use of drugs for alcohol use disorder in Norway 2004&#x02013;16].</article-title>
            <source>Tidsskr Nor Laegeforen</source>
            <year>2018</year>
            <month>Nov</month>
            <day>13</day>
            <volume>138</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">30421743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jophlin</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Singal</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Terrault</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>VH</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Alcohol-Associated Liver Disease.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2024</year>
            <month>Jan</month>
            <day>01</day>
            <volume>119</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-54</page-range>
            <pub-id pub-id-type="pmid">38174913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <chapter-title>Disulfiram</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">36153943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kranzler</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Soyka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Aug</month>
            <day>28</day>
            <volume>320</volume>
            <issue>8</issue>
            <fpage>815</fpage>
            <page-range>815-824</page-range>
            <pub-id pub-id-type="pmid">30167705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco-Gand&#x000ed;a</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Arias</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years.</article-title>
            <source>Eur J Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>05</day>
            <volume>836</volume>
            <fpage>89</fpage>
            <page-range>89-101</page-range>
            <pub-id pub-id-type="pmid">30096298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerzoni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pellesi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pini</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Caputo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review.</article-title>
            <source>Pharmacol Res</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>133</volume>
            <fpage>65</fpage>
            <page-range>65-76</page-range>
            <pub-id pub-id-type="pmid">29719204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frye</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Branch</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>53</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-62</page-range>
            <pub-id pub-id-type="pmid">11851639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghosh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mahintamani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Balhara</surname>
                <given-names>YPS</given-names>
              </name>
              <name>
                <surname>Roub</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mattoo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Mishra</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Disulfiram Ethanol Reaction with Alcohol-Based Hand Sanitizer: An Exploratory Study.</article-title>
            <source>Alcohol Alcohol</source>
            <year>2021</year>
            <month>Jan</month>
            <day>04</day>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-46</page-range>
            <pub-id pub-id-type="pmid">33150930</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r20">
          <label>20</label>
          <element-citation publication-type="book">
            <chapter-title>Disulfiram</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">31643433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhalla</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nehra</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Acute Disulfiram Poisoning in a Child: A Case Report and Review of Literature.</article-title>
            <source>Indian J Crit Care Med</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>203</fpage>
            <page-range>203-205</page-range>
            <pub-id pub-id-type="pmid">32435101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20621.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrulli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sestito</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tarli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mosoni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rando</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mirijello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Addolorato</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Alcohol addiction - the safety of available approved treatment options.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-177</page-range>
            <pub-id pub-id-type="pmid">29120249</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
